Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 32.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,700 shares of the medical research company’s stock after purchasing an additional 51,896 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Edwards Lifesciences were worth $14,102,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in shares of Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after acquiring an additional 809,605 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd lifted its position in Edwards Lifesciences by 17.8% in the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock worth $216,013,000 after purchasing an additional 494,604 shares during the period. Ownership Capital B.V. boosted its stake in Edwards Lifesciences by 1.2% during the 3rd quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company’s stock valued at $197,509,000 after purchasing an additional 34,597 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Edwards Lifesciences by 2.1% during the 2nd quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company’s stock valued at $192,403,000 after purchasing an additional 43,247 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Up 1.5 %

Shares of NYSE:EW opened at $70.56 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a market capitalization of $41.61 billion, a PE ratio of 10.18, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. The company has a fifty day moving average of $67.66 and a 200-day moving average of $75.83.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on EW shares. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Stifel Nicolaus reduced their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Barclays reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Finally, Wells Fargo & Company cut their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.